REQUEST MORE INFORMATION

Learn more about CUROSURF and get updates when new information becomes available. Please use the form below to give us your contact information and let us know how we can help you. We aim to respond to all inquiries within one business day.

By selecting one or both of the two options below, you are confirming that you have read and agreed to the terms of our
Privacy Policy.









    Terms and Conditions

      I want to be contacted by a Chiesi Sales Representative

      Title

      First name

      Last name

      Hospital name (optional)

      ZIP code

      Preferred method of contact

      EmailPhone

      Email address

      Primary role (optional)

      Terms and Conditions

        I want to be contacted by a Chiesi Sales Representative






        Preferred method of contact

        EmailPhone




        Terms and Conditions

        Medical Information

        To request specific medical information about CUROSURF or to report adverse events or product complaints, contact the Medical Information Department. Adverse events may also be reported to the FDA’s MedWatch Program at 1-800-FDA-1088.

        Phone

        1-888-661-9260

        IMPORTANT SAFETY INFORMATION

        CUROSURF® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.

        CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.

        Transient adverse reactions associated with administration of CUROSURF include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

        Pulmonary hemorrhage, a known complication of premature birth and very low birth-weight, has been reported with CUROSURF. The rates of common complications of prematurity observed in a multicenter single-dose study that enrolled infants 700–2000 g birth weight with RDS requiring mechanical ventilation and FiO2 ≥ 0.60 are as follows for CUROSURF 2.5 mL/kg (200 mg/kg) (n=78) and control (n=66; no surfactant) respectively: acquired pneumonia (17% vs. 21%), acquired septicemia (14% vs. 18%), bronchopulmonary dysplasia (18% vs. 22%), intracranial hemorrhage (51% vs. 64%), patent ductus arteriosus (60% vs. 48%), pneumothorax (21% vs. 36%) and pulmonary interstitial emphysema (21% vs. 38%).

        INDICATION

        CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

        Please see Full Prescribing Information.